{"organizations": [], "uuid": "9350032f3f8472eff98ea397ab67a63aa79f67b5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-jazz-pharmaceuticals-q4-gaap-earni/brief-jazz-pharmaceuticals-q4-gaap-earnings-per-share-3-79-idUSASB0C7T5", "country": "US", "domain_rank": 408, "title": "BRIEF-Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T23:19:00.000+02:00", "replies_count": 0, "uuid": "9350032f3f8472eff98ea397ab67a63aa79f67b5"}, "author": "", "url": "https://www.reuters.com/article/brief-jazz-pharmaceuticals-q4-gaap-earni/brief-jazz-pharmaceuticals-q4-gaap-earnings-per-share-3-79-idUSASB0C7T5", "ord_in_thread": 0, "title": "BRIEF-Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-jazz pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "jazz pharmaceuticals plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "  6 minutes ago BRIEF-Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79 Reuters Staff Feb 27 (Reuters) - Jazz Pharmaceuticals Plc: * JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS * Q4 ADJUSTED EARNINGS PER SHARE $2.95 * Q4 GAAP EARNINGS PER SHARE $3.79 * SEES ‍FULL YEAR 2018 REVENUES $1,860 MILLION -$1,930 MILLION ​ * SEES ‍FULL YEAR 2018 TOTAL NET PRODUCT SALES $1,845 MILLION -$1,910 MILLION ​ * SEES ‍FULL YEAR 2018 GAAP NET INCOME PER DILUTED SHARE $7.15-$8.45​ * SEES ‍FULL YEAR 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.65-$13.25​ * QTRLY ‍TOTAL REVENUES $436.4 MILLION VERSUS $ 396.6 MILLION ​ * Q4 EARNINGS PER SHARE VIEW $2.98, REVENUE VIEW $441.3 MILLION -- THOMSON REUTERS I/B/E/S * FY2018 EARNINGS PER SHARE VIEW $13.07, REVENUE VIEW $1.85 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-27T23:19:00.000+02:00", "crawled": "2018-02-27T23:27:38.004+02:00", "highlightTitle": ""}